Therapeutic Potential of Brazilian Cerrado Species on Metabolic Dysfunctions

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
simvastatin 2 endocrinologydiseasesdrugs
ciprofibrate 2 endocrinologydiseasesdrugs
glucose intolerance 1 endocrinologydiseases
hyperglycemia 4 endocrinologydiseases
hyperlipidemia 2 endocrinologydiseases
hypertriglyceridemia 3 endocrinologydiseases
metabolic syndrome 13 endocrinologydiseases
obesity 21 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ciprofibrate 36049 300 µL of water), HFD-S (HFD + 30 mg of simvastatin per kilogram of body weight), HFD-C (HFD + 2 mg ciprofibrate per kilogram of body weight), and HFD-ExCA (HFD + 200 mg of C. adamantium root aqueous extract per kilogram
ciprofibrate 36582 HFD group. Similar findings were observed in the HFD-S, HFD-C, and CT groups. Both simvastatin and ciprofibrate are two drugs that are currently used for the treatment of hypercholesterolemia and hypertriglyceridemia,
simvastatin 35989 therefore, were divided in four treatment groups: HFD (HFD + 300 µL of water), HFD-S (HFD + 30 mg of simvastatin per kilogram of body weight), HFD-C (HFD + 2 mg ciprofibrate per kilogram of body weight), and HFD-ExCA
simvastatin 36566 compared with the HFD group. Similar findings were observed in the HFD-S, HFD-C, and CT groups. Both simvastatin and ciprofibrate are two drugs that are currently used for the treatment of hypercholesterolemia and
Select Disease Character Offset Disease Term Instance
glucose intolerance 2981 correlation with type 2 diabetes (DM2), in which obese individuals are at risk patients to develop DM2 and glucose intolerance [[2]]. These are often seen together with dyslipidemia which is more observed in obese patients than
hyperglycemia 2330 disorders that are commonly related to the obesity context, such as cardiovascular disturbances and hyperglycemia status. This suggests that guavira is a potential therapeutic approach to obesity-induced metabolic
hyperglycemia 16770 assessed the potential use of C. xanthocarpa considering the variables of hypercholesterolemia and hyperglycemia , which are two conditions associated to obesity and related to the development of DM2 and cardiovascular
hyperglycemia 18042 treatment with leaf decoction, causing typical diabetes symptoms, such as polydipsia, polyuria, polyphagia, hyperglycemia , hypertriglyceridemia, and histopathological modifications in the liver, kidney, and pancreas [[50]].Only
hyperglycemia 19794 myricetin, quercitrin, and rutin, may be responsible for the effects of the decoction [[52]].Besides hyperglycemia , hyperlipidemia is another condition that presents a key role in the development of the micro- and macrovascular
hyperlipidemia 19809 quercitrin, and rutin, may be responsible for the effects of the decoction [[52]].Besides hyperglycemia, hyperlipidemia is another condition that presents a key role in the development of the micro- and macrovascular complications
hyperlipidemia 35775 effects in hyperlipidemic Wistar rats that received a high-fructose diet (HFD) for 16 weeks. After hyperlipidemia assessment, the animals continued receiving HFD concomitantly with an oral gavage treatment and, therefore,
hypertriglyceridemia 18057 decoction, causing typical diabetes symptoms, such as polydipsia, polyuria, polyphagia, hyperglycemia, hypertriglyceridemia , and histopathological modifications in the liver, kidney, and pancreas [[50]].Only the rats with a
hypertriglyceridemia 36679 and ciprofibrate are two drugs that are currently used for the treatment of hypercholesterolemia and hypertriglyceridemia , respectively. In this way, because hypertriglyceridemia is usually accompanied by high levels of cholesterol
hypertriglyceridemia 36736 the treatment of hypercholesterolemia and hypertriglyceridemia, respectively. In this way, because hypertriglyceridemia is usually accompanied by high levels of cholesterol [[81]], ExCA was able to reduce both of these conditions.
metabolic syndrome 1133 conjunction with other metabolic disorders such as insulin resistance and dyslipidemia, is a feature of metabolic syndrome which is characterized by a pro-inflammatory state and increased oxidative stress. Therefore, antioxidant
metabolic syndrome 2434 hyperglycemia status. This suggests that guavira is a potential therapeutic approach to obesity-induced metabolic syndrome .1. Introduction1.1. Obesity-Induced Metabolic Syndrome and Perspectives in Medicinal PlantsObesity is
metabolic syndrome 3247 hyperglycemic profile in obese patients is associated to acute insulin resistance which is similar to metabolic syndrome (MetS) which, in turn, is characterized by insulin resistance, hypertension, central obesity (abdominal
metabolic syndrome 3686 leading to a high incidence of mortality rate from cardiovascular diseases (CVDs) [[4]].Obesity-induced metabolic syndrome is predominantly a result of the synthetic function of adipose tissue due to the fact that this tissue
metabolic syndrome 4510 anti-atherogenic properties [[5],[6],[7],[8]].In this way, this pro-inflammatory profile on obesity-induced metabolic syndrome is a key factor in the stages of atherosclerosis, such as in the progression and destabilization that
metabolic syndrome 5202 lipoprotein (LDL-c), and a reduction in high density lipoprotein (HDL-c) are common in diabetic obese-induced metabolic syndrome individuals [[6],[7]].Moreover, another deleterious factor which is increased in MetS and DM2 and seems
metabolic syndrome 6005 of diseases, causing increased risks of insulin resistance, dyslipidemia, elevated blood pressure, metabolic syndrome , inflammation, and endothelial dysfunction [[10]]. It is established that ROS levels are increased in
metabolic syndrome 6580 of diseases and health support [[10],[14]]. These metabolic dysfunctions relating to obesity-induced metabolic syndrome may be significantly decreased by dietary modifications, physical activity, and antioxidant drugs. These
metabolic syndrome 7716 clarifications. Despite the fact that research on medicinal plants′ therapeutic potential on obesity-induced metabolic syndrome has increased substantially, specific medicinal plants in different biomes are important to study due
metabolic syndrome 13167 health and because of the concerns that involve metabolic dysfunctions associated to obesity-induced metabolic syndrome , a current study was conducted which demonstrated hypocholesterolemic, antioxidant, and anti-inflammatory
metabolic syndrome 13968 Campomanesia species in metabolic dysfunctions which may or may not be associated to obesity-associated metabolic syndrome , focusing on the possible mechanism of action in in vivo, including animal models and human clinical
metabolic syndrome 47095 that were already accomplished may be key points to be carried out in models of obesity-associated metabolic syndrome , since C. pubescens demonstrated anti-inflammatory and antioxidant properties (Table 3). Thus, further
metabolic syndrome 48819 concentrations, assess possible side effects, and determine mechanism of actions, especially in obesity-induced metabolic syndrome in animal models and human clinical trials.molecules-23-02336-t001_Table 1Table 1Principal effects of
obesity 2273 obese subjects, guavira demonstrated effects in metabolic disorders that are commonly related to the obesity context, such as cardiovascular disturbances and hyperglycemia status. This suggests that guavira is
obesity 2418 disturbances and hyperglycemia status. This suggests that guavira is a potential therapeutic approach to obesity -induced metabolic syndrome.1. Introduction1.1. Obesity-Induced Metabolic Syndrome and Perspectives in
obesity 3351 metabolic syndrome (MetS) which, in turn, is characterized by insulin resistance, hypertension, central obesity (abdominal fat), and dyslipidemia. Therefore, patients with MetS display a prothrombotic and pro-inflammatory
obesity 4494 anti-inflammatory, and anti-atherogenic properties [[5],[6],[7],[8]].In this way, this pro-inflammatory profile on obesity -induced metabolic syndrome is a key factor in the stages of atherosclerosis, such as in the progression
obesity 6126 inflammation, and endothelial dysfunction [[10]]. It is established that ROS levels are increased in obesity , especially in central (abdominal) obesity, being the major component of MetS [[11]]. In addition, others
obesity 6169 [[10]]. It is established that ROS levels are increased in obesity, especially in central (abdominal) obesity , being the major component of MetS [[11]]. In addition, others studies have demonstrated that augmented
obesity 6564 the prevention of diseases and health support [[10],[14]]. These metabolic dysfunctions relating to obesity -induced metabolic syndrome may be significantly decreased by dietary modifications, physical activity,
obesity 7700 necessary clarifications. Despite the fact that research on medicinal plants′ therapeutic potential on obesity -induced metabolic syndrome has increased substantially, specific medicinal plants in different biomes
obesity 13151 positive effects on health and because of the concerns that involve metabolic dysfunctions associated to obesity -induced metabolic syndrome, a current study was conducted which demonstrated hypocholesterolemic, antioxidant,
obesity 13949 Brazilian Cerrado Campomanesia species in metabolic dysfunctions which may or may not be associated to obesity -associated metabolic syndrome, focusing on the possible mechanism of action in in vivo, including animal
obesity 16649 reproductive toxicity [[48]].In the face of the increasing prevalence of metabolic disturbances related to obesity , some studies assessed the potential use of C. xanthocarpa considering the variables of hypercholesterolemia
obesity 16824 considering the variables of hypercholesterolemia and hyperglycemia, which are two conditions associated to obesity and related to the development of DM2 and cardiovascular events [[6]]. A preliminary study has evaluated
obesity 34100 understand the effects of C. xanthocarpa on metabolic dysfunctions that are commonly associated to the obesity profile. Therefore, the results have demonstrated that C. xanthocarpa, together with its bioactive compounds,
obesity 34287 with its bioactive compounds, promoted beneficial effects in pathological conditions associated to obesity (Table 1).2.2. Campomanesia adamantium (Cambess.) O. BergC. adamantium (Cambess.) O. Berg is also found
obesity 35381 effects [[33],[34],[35],[36],[79]], and antimicrobial activity [[80]].Regarding studies that focus on obesity and its endocrine dysfunctions, there are still few studies that demonstrate the effects of C. adamantium
obesity 42681 necessary to investigate the potential of C. adamantium on pathological conditions associated with obesity , in vivo studies are still necessary to evaluate the bioavailability of these bioactive compounds in
obesity 42931 biological system (Table 2), concomitant with the evaluation of metabolic parameters associated to obesity and the bioactive compound′s mechanisms of action.2.3. Campomanesia pubescens O. BergC. pubescens
obesity 46950 studies related to the C. pubescens variety, especially regarding metabolic dysfunctions associated to obesity , are still scarce. However, the works that were already accomplished may be key points to be carried
obesity 47076 However, the works that were already accomplished may be key points to be carried out in models of obesity -associated metabolic syndrome, since C. pubescens demonstrated anti-inflammatory and antioxidant properties
obesity 48384 cancers, along with antioxidant capacity. Regarding the concern of metabolic disturbances associated to obesity , the use of Campomanesia species in the treatment of metabolic disorders is still under investigation.
obesity 48803 safe concentrations, assess possible side effects, and determine mechanism of actions, especially in obesity -induced metabolic syndrome in animal models and human clinical trials.molecules-23-02336-t001_Table

You must be authorized to submit a review.